[Top Page]

Link to other pages

[first sentense]

Our CSV Commitment Health and Well-being

Supporting self-care for healthy people and people with pre-disease

SDGs
Goals/Targets
3 GOOD HEALTH AND WELL-BEING

By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being (Target:3.4)

Our Commitment 1.1
We will help consumers manage their daily energy (calories/kilojoules) and nutrient intake through providing a balanced portfolio of products and information-helping them address major noncommunicable diseases, including obesity.
Our story
Today, preventing noncommunicable diseases is an urgent social challenge in many countries around the world. We aim to help consumers manage their health and well-being through the food and beverage products and information we provide, every day.
Our approach

Our food and beverage (F&B) businesses will provide a balanced portfolio of products, with optimized energy and nutrition—without compromising taste and safety. Specifically, each F&B business will commit to some or all of the following, relevant to their local markets’ health priorities:

to reduce added sugar, salt, and fat;
to increase the availability of sugar-free, and lower-sugar and lower-energy options;
to have smaller pack sizes available across the product portfolio;
to improve the nutrition and product information available to consumers;
to provide consumers with educational advice on achieving a balanced diet and lifestyle;
to enhance R&D efforts to provide an optimal portfolio of products for consumers.
Our outcomes
Specific targets will be developed,aligned to our approach.
SDGs
Goals/Targets
9 INDUSTRY, INNOVETION AND INFRASTRUCTURE

Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and substantially increasing the number of research and development workers per 1 million people and public and private research and development spending (Target:9.5)

Our Commitment 1.2
We will contribute to enhancing customers’ quality of life throughout their lifetime, and strive to create revolutionary products, services, and new businesses.
Our story
Living healthily and happily throughout one’s lifetime is an important theme in modern society, particularly for us living in Japan, an advanced country taking on serious social issues, including an aging society. With our foundation in the beverage and pharmaceutical/bio-chemical businesses, the Kirin Group contributes to a broad range of our customers’ life stages, and through this contribution, we will work on a range of initiatives to enable all people to maximize their ability to live a healthy life, both physically and mentally—in other words, enhance our customers’ quality of life.
Our approach

By horizontally utilizing the technologies, assets, and customer touchpoints that exist both inside and outside the Group, we will create new value that supports customers’ daily physical and mental health, including:

to quickly develop high-quality products using the materials and technologies created through our sincere research efforts in the bioscience field;
to expand the POCT* product business based on our experience in the medical treatment field, considering the possibility to expand into the area of pre-symptomatic diseases through collaboration with external partners.
*
POCT: Point Of Care Testing, which means real time and on-site testing by healthcare workers alongside subjects with the use of portable, simple equipment and reagent kits
Our outcomes
Launch multiple new products, services, and businesses by 2021.

Evolution in medical treatment

SDGs
Goals/Targets
3 GOOD HEALTH AND WELL-BEING

Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all (Target:3.8)

Our Commitment 1.3
We will continuously discover innovative drugs and expand our commercialization activities globally. (Kyowa Hakko Kirin)
Our story
Along with the overall progress of science, new medical technologies and medicines are being developed, but there are still many patients suffering from diseases that do not yet have a satisfactory treatment. Medical needs that are not being met are becoming increasingly more diversified and highly specialized, and the development of new drugs that respond to such needs is facing more hurdles in terms of technology and cost. In such an environment, however, through state-of-the-art biotechnology we can create new value by offering innovative medicines and expanding indications and dosage forms. With these advancements, we will contribute to people’s health and well-being around the world.
Our approach
Based on the strengths of R&D and manufacturing technology cultivated through the provision of biopharmaceuticals, we will strengthen our drug discovery format and create drug candidates continuously while effectively utilizing open innovation in each technology field positioned as four drug discovery modalities, i.e., therapeutic antibodies, small molecule drugs, nucleic acid drugs, and regenerative medicine.
Obtain approval and begin sales overseas of globally strategic pharmaceuticals: KRN23 treatment for X-linked hypophosphatemic rickets (XLH), KW-0761 treatment for adult T-cell leukemia-lymphoma and cutaneous lymphoma, and KW-6002 treatment for Parkinson’s disease, and aim to be a Global Specialty Pharmaceutical Company. -We will proceed with the development of biosimilars and aim to quickly obtain manufacturing and marketing approval and begin sales.
Our outcomes
Quickly begin sales in the European and U.S. markets of KRN23 treatment for X-linked hypophosphatemic rickets (XLH), KW-0761 treatment for adult T-cell leukemia-lymphoma and cutaneous lymphoma, and KW-6002 treatment for Parkinson’s disease.
SDGs
Goals/Targets
3 GOOD HEALTH AND WELL-BEING

Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all (Target:3.8)

Our Commitment 1.4
By providing inexpensive, high quality biosimilars and “Authorized versions” of biologics, we will contribute to the further use of biomedicines and to solving a global issue, increases in healthcare spending. (Kyowa Hakko Kirin)
Our story
Limiting the increases in social security spending (healthcare spending) is an important global issue. One of the expected solutions is the increased use of generics and biosimilars. Using the technology we have developed over the years, we will proceed with the development, manufacture, and sales of high-quality antibody biosimilars. Additionally, in the Japanese market, in which biosimilars do not yet have a sufficient presence, we will contribute to improving human health and to limiting healthcare spending by launching “Authorized versions” of our biologics.
Our approach
We will proceed with the development of biosimilars and aim to quickly obtain manufacturing and marketing approval and begin sales.
We will establish a new company with the aim of obtaining manufacturing and marketing approval in Japan for an “Authorized version” of NESP®.
Our outcomes
Quickly begin sales of biosimilars in accordance with the patent environment in each country and region.
Aim to obtain approval in Japan for an “Authorized version” of NESP®.

Health-oriented business management

SDGs
Goals/Targets
3 GOOD HEALTH AND WELL-BEING

By 2030, reduce by one third premature mortality from noncommunicable diseases through prevention and treatment and promote mental health and well-being (Target:3.4)

Our Commitment 1.5
As a company that delivers products and services contributing to consumer health, we will create an environment and opportunity for our employees to proactively improve their own health.
We will address any mental health issues facing our employees and work to prevent lifestyle-related diseases. Also, as a member of the alcohol beverage industry, we will promote responsible drinking that encourages employees to be role models for society.
Our story
Employee physical and mental health problems are getting worse due to recent changes in the working environment. As a company that redefines the joy of food and well-being, we will create an environment where our employees can work vigorously and where we can build strong organizational capabilities so that we can create new innovations that deliver new value to our customers.
Our approach
Working environment:
We will build up internal systems to realize a flexible way of working and create an environment where our employees can proactively improve their health. At the same time, we will raise their awareness so that the above initiatives can work more effectively.
Mental health, lifestyle-related diseases, and leadership in responsible drinking as a role model: Based on comprehensive information and with the assistance of medical experts, we will educate and instruct our employees in health-related matters.
Our outcomes
Build up internal systems and promote activities to realize flexible working styles.
Reduce the number of employees who have problems involving mental health issues, lifestylerelated diseases, and inappropriate drinking.

Safety and security of our products

SDGs
Goals/Targets
2 ZERO HUNGER

By 2030, ensure sustainable food production systems and implement resilient agricultural practices that increase productivity and production, that help maintain ecosystems, that strengthen capacity for adaptation to climate change, extreme weather, drought, flooding and other disasters and that progressively improve land and soil quality (Target:2.4)

Our Commitment 1.6
We will establish a hygiene management system for the production process based on global standards* and continue to work on improving product safety. Also, we will enhance communication related to quality in order to build trust and increase a sense of security among our customers.
*
HACCP: Hazard Analysis and Critical Control Point
Our story
Driven by a number of events threatening food safety including food terrorism, food-related fraud, and food poisoning by norovirus, the interest in product safety and security is growing. We work on ensuring product safety and customer satisfaction as a top priority based on the Kirin Group’s quality policy, “Customeroriented and Quality first.” We listen to our customers with sincerity, value our communication with them, and provide information that builds their trust.
Our approach
We will build a global hygiene management system for the production process based on HACCP.
We will communicate information about our initiatives for ensuring raw material safety, including residual agricultural chemicals and radioactive substances, to our customers.
We will communicate product and raw material information that meets customers’ expectations by utilizing various touchpoints including company websites, in-store programs, and plant tours.
Our outcomes
Set target in 2017 regarding the hygiene management system.
Improve customers’ sense of security in our product quality and their trust in the Kirin brand through their deep understanding of our products and raw materials.

List of commitments

[footer]

© 2007 Kirin Holdings Company, Limited.

Back to top